NEW YORK, March 6, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Regeneron Pharmaceuticals, Inc. Analyst Notes
On February 27, 2014, Regeneron Pharmaceuticals, Inc.'s (Regeneron) stock increased 0.61%, ending the day at $338.54. Over the previous three trading sessions, shares of Regeneron declined 2.61%, compared to the Nasdaq Composite Index which increased 0.60% during the same period. The full analyst notes on Regeneron Pharmaceuticals, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03062014/REGN/report.pdf
--
DENTSPLY International Inc. Analyst Notes
On February 18, 2014, DENTSPLY International Inc. (DENTSPLY) reported its financial results for Q4 2013 and 2013. Q4 2013 net sales remained flat at $753.7 million on a year-on-year basis, while the same gained 0.8% YoY to $2.95 billion in 2013. Net income attributable to DENTSPLY for Q4 2013 was $74.4 million, or $0.51 per diluted share, versus $126.8 million, or $0.88 per diluted share, in Q4 2012. For 2013, net income attributable to DENTSPLY stood at $313.2 million or $2.16 per diluted share, compared with $314.2 million or $2.18 per diluted share in 2012. Bret Wise, Chairman and CEO, commented, "We continue to be pleased with the progress we have made in accelerating earnings growth over the past few quarters, as we realize benefits from our integration and cost savings activities. Looking ahead, we see opportunities to continue to drive market share growth across our global portfolio by leveraging our core strategies of innovation, clinical education and sales force effectiveness. We believe that global market conditions will improve slightly in 2014 and, accordingly, we are expecting adjusted earnings in the range of $2.45 to $2.55 per share, representing growth in the range of 4% to 9% for the year." The full analyst notes on DENTSPLY International Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03062014/XRAY/report.pdf
--
AMAG Pharmaceuticals, Inc. Analyst Notes
On February 25, 2014, AMAG Pharmaceuticals, Inc. (AMAG) announced the appointment of Edward Jordan as Senior Vice President of sales and marketing. William Heiden, President and CEO of AMAG, commented, "I have known Ed for many years, and am confident that, with his deep experience in pharmaceutical and device commercial leadership, he will be a great addition to our executive team. Ed's ability to build and lead top-performing commercial teams will be a great asset to AMAG as we continue to drive market share growth and market expansion for our current products." Jordan added, "I am very pleased to be joining AMAG. It is an exciting time; coming off such a successful 2013 and well positioned for significant growth and success. I look forward to leading the commercial team and contributing to the company's goals of continuing to grow Feraheme and MuGard sales, expanding the product portfolio and building a multi-product, profitable specialty pharmaceutical company." The full analyst notes on AMAG Pharmaceuticals, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03062014/AMAG/report.pdf
--
Cadence Pharmaceuticals Inc. Analyst Notes
On February 27, 2014, Cadence Pharmaceuticals Inc.'s (Cadence) stock increased 0.14%, ending the day at $14.02. Over the previous three trading sessions, shares of Cadence increased 0.36%, compared to the Nasdaq Composite Index which increased 0.60% during the same period. The full analyst notes on Cadence Pharmaceuticals Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03062014/CADX/report.pdf
--
ArthroCare Corporation Analyst Notes
On February 27, 2014, ArthroCare Corporation's (ArthroCare) stock increased 0.04%, ending the day at $48.28. Over the previous three trading sessions, shares of ArthroCare declined 0.35%, compared to the Nasdaq Composite Index which increased 0.60% during the same period. The full analyst notes on ArthroCare Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03062014/ARTC/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://AnalystsReview.com
SOURCE Analysts Review
